Sab Biotherapeutics Inc. has obtained human research ethics committee (HREC) approval in Australia to commence a first-in-human phase I trial investigating SAB-142 for type 1 diabetes.
An artificial intelligence (AI) algorithm using voice technology developed by Klick Inc. could be a game changer for diagnosis of type 2 diabetes, helping to identify the 50% of individuals who unknowingly have the disease. The technology uses a six- to 10-second voice clip spoken into a smartphone plus basic health data to detect diabetes in close to nine out of 10 individuals, a study published in Mayo Clinic Proceedings: Digital Health found.
Ventus Therapeutics US Inc. has divulged pyrido-[3,4-d]pyridazine amine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic, autoimmune disease, liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Huadong Medicine Co. Ltd. recently detailed the discovery and preclinical characterization of a potent and selective small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, HDM-1002, under investigation for the treatment of type 2 diabetes and obesity.
“Finally!” Piper Sandler analysts cheered in a research note on Ardelyx Inc., which after spending three years battling the U.S. FDA, secured approval of Xphozah (tenapanor) for treating hyperphosphatemia in adults with chronic kidney disease (CKD). The company will waste no time getting to market, aiming to have the NHE3 inhibitor available to patients next month, marking the first new treatment class for hyperphosphatemia in 30 years.
Bloomsbury Genetic Therapies Ltd. has announced U.S. and E.U. orphan drug designations for BGT-NPC, an investigational gene therapy for the treatment of Niemann-Pick disease type C (NPC). BGT-NPC is an investigational AAV9 gene therapy designed to provide a potentially curative solution to NPC patients following a one-time injection in the cerebrospinal fluid.
M-43 is a recombinant analogue of fibroblast growth factor-1 (FGF-1) that has been previously shown to bind the insulin receptor (InsR), activate insulin-like cellular signaling and reduce insulin resistance. Researchers from Celon Pharma SP have recently presented results on the efficacy of the candidate as assessed in Zucker diabetic fatty (ZDF) rats.
Scholar Rock Inc. has announced plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity, toward an IND submission in 2025.
A team from Atrogi AB has reported the activity of ATR-127, a novel dual adrenergic agonist targeting β2- and β3-adrenoceptors (ARs), for the potential treatment of steatohepatitis, obesity and diabetes.
Researchers from Yuhan Corp. presented the discovery and preclinical evaluation of a novel long-acting dual agonist of the glucagon like peptide-1 (GLP-1) and growth differentiation factor 15 (GDF-15), YH-40863.
RSS
